393
Participants
Start Date
March 15, 2019
Primary Completion Date
August 31, 2026
Study Completion Date
August 31, 2026
zolbetuximab
Administered as an intravenous infusion.
nab-paclitaxel
Administered as an intravenous infusion
gemcitabine
Administered as an intravenous infusion
Site ES34014, Cáceres
Memorial Sloan-Kettering Cancer Center, New York
Site IT39004, Candiolo
Memorial Sloan Kettering Westchester, Harrison
Northwell Health Cancer Institute, Lake Success
Memorial Sloan Kettering Nassau, Uniondale
Memorial Sloan Kettering Commack, Commack
Site FR33015, Caen
Roswell Park Cancer Institute, Buffalo
Site IT39006, Rozzano
Site IT39003, Milan
Site FR33014, Plérin
Site ES34005, Lleida
Site IT39002, Cremona
Novant Health, Winston-Salem
Site ES34015, Madrid
Site ES34006, Madrid
Site ES34009, Madrid
Novant Health Presbyterian Medical Center, Charlotte
Cancer Treatment Centers of Atlanta, Newnan
Site ES34003, Pamplona
Baptist Health, Miami
Lynn Cancer Institute, Boca Raton
Site FR33003, Aquitaine
Site FR33006, Chambray
Norton Cancer Institute (NCI), Louisville
Site FR33016, La Chaussée-Saint-Victor
Site FR33012, Herblain
Site FR33009, Nancy
University of Illinois at Chicago, Chicago
David C Pratt Cancer Center, Creve Coeur
Site FR33001, Bayonne
Site FR33007, Strasbourg
Ochsner Health System, New Orleans
Site FR33005, Pringy
Site FR33017, Rouen
Houston Methodist Hospital, Houston
Utah Cancer Specialists, Salt Lake City
TOI Clinical research, Whittier
St. Joseph Heritage Medical Group, Fullerton
Site FR33013, Villejuif
Virginia Mason, Seattle
MultiCare Regional Cancer Center - Gig Harbor, Gig Harbor
Vista Oncology, Olympia
Midstate Medical Center, Meriden
Memorial Sloan Kettering Basking Ridge, Basking Ridge
Memorial Sloan Kettering Bergen, Montvale
Site AU61008, Gosford
Site AU61007, Wollongong
Site AU61005, Fitzroy
Site AU61006, Warrnambool
Site BR55012, Porto Alegre
Site BR55009, Centro Passo Fundo
Site BR55008, Rio Grande
Site BR55004, Santa Catarina
Site BR55010, São Paulo
Site BR55011, São Paulo
Site CN86001, Beijing
Site CN86008, Beijing
Site CN86014, Beijing
Site CN86026, Changchun
Site CN86009, Chongqing
Site CN86004, Guangdong
Site CN86020, Guangdong
Site CN86016, Guangzhou
Site CN86012, Harbin
Site CN86002, Hubei
Site CN86005, Jiangsu
Site CN86011, Jiangsu
Site CN86025, Jiangsu
Site CN86023, Shandong
Site CN86006, Shanghai
Site CN86013, Shanghai
Site CN86019, Shanghai
Site CN86007, Tianjin
Site CN86022, Xinjiang
Site CN86024, Yanxi
Site CN86003, Zhejiang
Site CN86018, Zhejiang
Site CN86010, Zhengzhou
Site FR33018, Bordeaux
Site FR33002, Grenoble
Site FR33019, La Roche-sur-Yon
Site FR33021, Nice
Site FR33023, Pierre-Bénite
Site IT39010, Lombardia
Site IT39014, Toscana
Site IT39008, Veneto
Site JP81007, Nagoya
Site JP81001, Kashiwa
Site JP81005, Sapporo
Site JP81006, Yokohama
Site JP81003, Kashihara
Site JP81011, Bunkyo-ku
Site JP81012, Chuo-ku
Site JP81014, Koto-ku
Site JP81013, Mitaka
Site JP81002, Shinjuku-ku
Site JP81015, Ube
Site JP81004, Fukuoka
Site JP81010, Osaka
Site JP81009, Wakayama
Site MX52004, Distrito Federal
Site MX52003, San Luis Potosí City
Site MX52005, Veracruz
Site KR82008, Suwon
Site KR82010, Daegu
Site KR82009, Gyeonggi-do
Site ES34018, Barcelona
Site ES34021, Barcelona
Site ES34022, Córdoba
Site ES34026, Málaga
Site ES34017, Santiago de Compostela
Site TW88608, New Taipei City
Site TW88609, Taipei
Site TR90004, Ankara
Site TR90006, Ankara
Site TR90003, Diyarbakır
Site TR90002, Istanbul
Site TR90001, Konya
Site FR33008, Besançon
Site FR33010, Brest
Site IR35301, Elm Park
Site KR82005, Seongnam-si
Site KR82001, Seoul
Site KR82003, Seoul
Site KR82004, Seoul
Site KR82007, Seoul
Site KR82002, Seoul
Site KR82006, Seoul
Site ES34004, Llobregat
Site ES34010, Barcelona
Site ES34013, Barcelona
Site ES34007, Barcelona
Site TW88602, Taichung
Site TW88601, Taipei
Astellas Pharma Global Development, Inc.
INDUSTRY